Today in the United States, five million people over the age of 65 are suffering from Alzheimer's Disease. It's the 6th leading cause of death, and according to Medical News Today, it's the only cause of death in the Top 10 that there isn't a known way to treat, prevent or slow. There is also evidence that the disease may start affecting the brain up to 10 years before a clinical symptom can be recognized.
What can advance our knowledge of the disease? What we don't know about the disease, which is a big factor, is what causes it. Two of them any things that are currently standing in the way of Alzheimer's research are lack of patients to participate in clinical trials and lack of funding. However, that doesn't mean researchers have stopped doing research.
On September 18, Frederick T. Lewis, D.O., Vice President Neurosciences, Scientific Affairs at PRA Health Sciences, will be presenting the web seminar Drug Development in Alzheimer’s Disease: Reasons to Remain Optimistic. Join us from 10:00AM ET- 11:00 AM ET to find out more about what's going on in research for this disease and ask our expert questions you may have in our live Q&A discussion at the end of the presentation. Sign up here and mention priority code XP2000W1BLOG.
The Partnerships in Clinical Trials Blog focuses on optimization intelligence, regulatory trends and globalization strategies for both sponsors and CROs. It is supported by a number of industry events.
Would you like to guest blog on our site? Or send us feedback? Send an email to firstname.lastname@example.org.